{"id":"drsp-ee","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-10","effect":"Breakthrough bleeding"},{"rate":"2-5","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Drospirenone is a fourth-generation progestin with antimineralocorticoid activity, while ethinyl estradiol is a synthetic estrogen. Together, they suppress the luteinizing hormone (LH) surge needed for ovulation and increase cervical mucus viscosity to prevent sperm penetration. The progestin component also alters the endometrium to reduce implantation likelihood.","oneSentence":"DRSP-EE is a combined oral contraceptive containing drospirenone (a progestin) and ethinyl estradiol (an estrogen) that prevents ovulation and alters cervical mucus to inhibit fertilization.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:08.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception (prevention of pregnancy)"},{"name":"Treatment of acne vulgaris (in females)"},{"name":"Treatment of premenstrual dysphoric disorder (PMDD)"}]},"trialDetails":[{"nctId":"NCT07235774","phase":"PHASE1","title":"A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants","status":"RECRUITING","sponsor":"Institut de Recherches Internationales Servier (I.R.I.S.)","startDate":"2025-11-05","conditions":"Healthy Adult Female Participants","enrollment":28},{"nctId":"NCT07074327","phase":"PHASE1","title":"Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-07-11","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":74},{"nctId":"NCT06186271","phase":"","title":"International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2025-04-24","conditions":"Contraception","enrollment":68100},{"nctId":"NCT06028555","phase":"","title":"International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study","status":"RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2023-06-28","conditions":"Contraception, Birth Control","enrollment":101000},{"nctId":"NCT06820307","phase":"PHASE1","title":"Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-02-25","conditions":"Pain","enrollment":50},{"nctId":"NCT06775730","phase":"PHASE1","title":"A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants","status":"COMPLETED","sponsor":"Shionogi","startDate":"2024-12-30","conditions":"Healthy Adult Female Participants","enrollment":24},{"nctId":"NCT05934942","phase":"PHASE1","title":"A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2023-09-08","conditions":"Healthy","enrollment":29},{"nctId":"NCT01277211","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-09-19","conditions":"Contraception","enrollment":983},{"nctId":"NCT05985590","phase":"PHASE1","title":"A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-08-18","conditions":"Healthy Volunteers","enrollment":37},{"nctId":"NCT03091595","phase":"PHASE2","title":"E4/DRSP Ovarian Function Inhibition Study","status":"COMPLETED","sponsor":"Estetra","startDate":"2017-02-07","conditions":"Prevention of Pregnancy","enrollment":82},{"nctId":"NCT00413062","phase":"PHASE3","title":"Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-06","conditions":"Contraception","enrollment":2281},{"nctId":"NCT00511433","phase":"PHASE3","title":"Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-10","conditions":"Contraception","enrollment":48},{"nctId":"NCT00511199","phase":"PHASE3","title":"Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-05-01","conditions":"Contraception","enrollment":2152},{"nctId":"NCT01266408","phase":"","title":"INAS-FOCUS (International Active Surveillance Study - Folate in Oral Contraceptives Utilization Study)","status":"COMPLETED","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2010-11-22","conditions":"Contraception","enrollment":82921},{"nctId":"NCT02710708","phase":"PHASE4","title":"YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-05-27","conditions":"Contraception","enrollment":1921},{"nctId":"NCT02957630","phase":"PHASE1, PHASE2","title":"\"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study\"","status":"COMPLETED","sponsor":"Estetra","startDate":"2016-09","conditions":"Contraception, Liver Metabolism, Hemostasis Parameter","enrollment":101},{"nctId":"NCT01254292","phase":"PHASE3","title":"LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01-06","conditions":"Contraception","enrollment":567},{"nctId":"NCT01360996","phase":"PHASE4","title":"Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism","status":"COMPLETED","sponsor":"Woman's","startDate":"2011-08","conditions":"Polycystic Ovary Syndrome","enrollment":64},{"nctId":"NCT00511797","phase":"PHASE2, PHASE3","title":"SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-07","conditions":"Dysmenorrhea","enrollment":249},{"nctId":"NCT01902264","phase":"PHASE3","title":"Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-08","conditions":"Contraception","enrollment":34},{"nctId":"NCT02617537","phase":"PHASE3","title":"To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2016-01","conditions":"Dysmenorrhea","enrollment":""},{"nctId":"NCT00818519","phase":"PHASE3","title":"GA YAZ ACNE in China Phase III","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":179},{"nctId":"NCT00185484","phase":"PHASE3","title":"Efficacy and Safety Oral Contraceptive Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Contraception","enrollment":1113},{"nctId":"NCT00651846","phase":"PHASE4","title":"Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-06","conditions":"Healthy","enrollment":43},{"nctId":"NCT00656981","phase":"PHASE3","title":"Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-01","conditions":"Acne Vulgaris","enrollment":541},{"nctId":"NCT00651469","phase":"PHASE3","title":"Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-01","conditions":"Acne Vulgaris","enrollment":534},{"nctId":"NCT01257984","phase":"PHASE3","title":"Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-12","conditions":"Contraception","enrollment":508},{"nctId":"NCT01076582","phase":"PHASE3","title":"Comparative Trial in Hormone Withdrawal Associated Symptoms","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-04","conditions":"Oral Contraceptive","enrollment":592},{"nctId":"NCT00673686","phase":"PHASE2","title":"Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-05","conditions":"Contraceptives, Oral","enrollment":105},{"nctId":"NCT01331655","phase":"PHASE3","title":"Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America","status":"WITHDRAWN","sponsor":"Bayer","startDate":"2013-04","conditions":"Contraception","enrollment":""},{"nctId":"NCT00468481","phase":"PHASE3","title":"Efficacy and Safety Study for an Oral Contraceptive Containing Folate","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-04","conditions":"Neural Tube Defects, Contraception, Oral Contraceptives (OC)","enrollment":385},{"nctId":"NCT00367276","phase":"PHASE3","title":"Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-12","conditions":"Healthy","enrollment":221},{"nctId":"NCT01258660","phase":"PHASE1","title":"Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-12","conditions":"Contraception","enrollment":172},{"nctId":"NCT01253174","phase":"PHASE1","title":"Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-08","conditions":"Contraception","enrollment":48},{"nctId":"NCT01253187","phase":"PHASE1","title":"Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin)","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-10","conditions":"Contraception","enrollment":44},{"nctId":"NCT00461305","phase":"PHASE2, PHASE3","title":"Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-02","conditions":"Dysmenorrhea","enrollment":420},{"nctId":"NCT01319500","phase":"","title":"Drug Utilization Study on the Prescribing Indications for Yasmin® and Other OCs in Croatia","status":"COMPLETED","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2009-02","conditions":"Contraception","enrollment":3776},{"nctId":"NCT01590849","phase":"PHASE3","title":"Assessment of Autonomic Tone in Normotensive Women Using Combined Hormonal Oral Contraceptive Containing Drospirenone","status":"UNKNOWN","sponsor":"Instituto do Coracao","startDate":"2011-01","conditions":"Contraceptive Affecting the Autonomic Nervous System, Contraceptive Affecting Blood Pressure","enrollment":69},{"nctId":"NCT01482338","phase":"PHASE4","title":"Premenstrual Symptoms Treatment Comparing Between Oral Contraceptives Containing Desogestrel and Drospirenone","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2011-06","conditions":"Premenstrual Syndrome","enrollment":90},{"nctId":"NCT01198444","phase":"","title":"To Evaluate Compliance to Treatment Regimen (Rate of Deviations From the Prescribed Regimen) in Polish Females Treated With Different Low Dose Oral Contraceptives","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Contraception","enrollment":11884}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":51,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Yasmin","SCH 900121"],"phase":"phase_3","status":"active","brandName":"DRSP-EE","genericName":"DRSP-EE","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DRSP-EE is a combined oral contraceptive containing drospirenone (a progestin) and ethinyl estradiol (an estrogen) that prevents ovulation and alters cervical mucus to inhibit fertilization. Used for Contraception (prevention of pregnancy), Treatment of acne vulgaris (in females), Treatment of premenstrual dysphoric disorder (PMDD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}